Amarantus BioScience Holdings, Inc. – "#C4CT Wrap-up and the Decision to Present Interim LP-002 Data"

Publishing & Media

Share Tweet

Amarantus BioScience Holdings, Inc. – "#C4CT Wrap-up and the Decision to Present Interim LP-002 Data"

New York, NY / August 4, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his blog, CEO Gerald Commissiong discusses the successful #C4CT Summit held on July 31st at the United Nations, including details on the information presented in regard to the Company's LymPro Test for Alzheimer's disease. Mr. Commissiong stated, "We are well positioned to continue forward with our LymPro program and remain on track to achieve our corporate objectives by the end of 2014." Read the full blog post from Mr. Gerald Commissiong on (

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment.